|
The BSD
500 is ideally suited for combined use with the microSelectron-HDR
Brachytherapy system. Interstitial antennae fit neatly into plastic
brachytherapy catheters.
The operator simply inserts antennae and treats the tumor before or after
afterloading. HDR brachytherapy is easily imported into hyperthermia
planning system. Outpatient interstitial thermoradiotherapy is “convenient,
safe and efficacious.” -Johns Hopkins report in Cancer
Touch Screen Technology provides ease of control |
|
Improve your clinical results by adding
Hyperthermia. Pelvic Tumors—Cervix
“3-year overall survival rate was 27% in the radiotherapy group and
51% in the radiotherapy plus hyperthermia group.”
THE LANCET vol. 355 April 1, 2000
Breast Cancer
“…The overall CR rate for RT alone was 41% and for the combined
(HT+RT) treatment arm was 59%.”
Int. J. Radiation Oncology Biol. Phys. Vol. 35 No. 4, 1996
Prostate Cancer
“…patients with symptomatic, locally advanced, previously irradiated
and hormone refractory prostate cancer were treated with further irradiation
and external hyperthermia. All patients had complete resolution of symptoms
lasting for 12-24 months.”
The British Journal of Radiology 74 (2001) 745-751
Head and Neck
“Complete response occurred in 24 patients (89%), partial in 3
(11%)…The results of this study indicate that outpatient interstitial
thermoradiotherapy is convenient, safe and efficacious in treating human
neoplasms.”
Cancer 1996: 77:2363-70
Melanoma
“Invariate analysis showed a beneficial effect of hyperthermia
(radiation alone 28% vs combined treatment 46%)…Adjuvant hyperthermia
significantly improved local tumor control when applied in association with
radiation in treatment of malignant melanoma.”
THE LANCET vol. 345 March 4, 1995
Glioblastoma Maltiforme
“TTP and survival were significantly longer for “heat than ‘no heat’;
median survival 85 weeks vs 76 weeks; 2-year survival 31% vs 15%…Adjuvant
interstitial brain HT, given before and after brachytherapy boost, after
conventional radiotherapy significantly improves survival of patients with
focal glioblastoma with acceptable toxicity.”
Int. J. Radiation Oncology Biol. Phys. Vol. 40, No. 2, pp
287-295, 1998 |
